Bibliothek

Sprache
Bevorzugter Suchindex
Ergebnisse pro Seite
Sortieren nach
Sortierung
Anzahl gespeicherter Suchen in der Suchhistorie
E-Mail-Adresse
Voreingestelltes Exportformat
Voreingestellte Zeichencodierung für Export
Anordnung der Filter
Maximale Anzahl angezeigter Filter
Autovervollständigung
Feed-Format
Anzahl der Ergebnisse pro Feed
feed icon rss

Ihre E-Mail wurde erfolgreich gesendet. Bitte prüfen Sie Ihren Maileingang.

Leider ist ein Fehler beim E-Mail-Versand aufgetreten. Bitte versuchen Sie es erneut.

Vorgang fortführen?

Exportieren
  • 1
    Digitale Medien
    Digitale Medien
    Springer
    Clinical and experimental nephrology 3 (1999), S. 296-299 
    ISSN: 1437-7799
    Schlagwort(e): Key words Vancomycin ; Multiple organ failure ; Continuous hemodiafiltration ; Pharmacokinetics
    Quelle: Springer Online Journal Archives 1860-2000
    Thema: Medizin
    Notizen: Abstract Background. Some pharmacokinetic data for vancomycin (VCM) during continuous arteriovenous hemofiltration have been reported, but reports on the effect of continuous venovenous hemodiafiltration (CVVHDF), which is more commonly performed in patients with multiple organ failure (MOF), on VCM pharmacokinetics are scanty. Method. We selected five patients with MOF with serious infection with methicillin-resistant Staphylococcus aureus who needed treatment with VCM during CVVHDF. Blood flow rate was 80 ml/min, and dialysis fluid flow rate and filtration flow rate were both 0.5 l/h. A hemofilter made of polysulfon was used. After administration of 0.5–1.0 g of VCM, serial samples of blood and dialysate/filtrate outflow were obtained during CVVHDF. Pharmacokinetic parameters were calculated by a standard model-independent method. Results. Mean ± SE values for the pharmacokinetic parameters of VCM were: elimination rate constant, 0.0369 ± 0.0124/h; systemic clearance, 25.6 ± 5.0 ml/min; CVVHDF clearance, 15.9 ± 3.4 ml/min; non-CVVHDF clearance, 9.6 ± 8.4 ml/min; and distribution volume, 51.1 ± 21.6 l. The harmonic mean of half-life was 18.9 h. Conclusion. The systemic clearance of VCM during CVVHDF was relatively higher than anticipated. The pharmacokinetic parameters obtained in the present study will be useful to optimize the dose schedule of VCM in patients with MOF being treated with CVVHDF.
    Materialart: Digitale Medien
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
Schließen ⊗
Diese Webseite nutzt Cookies und das Analyse-Tool Matomo. Weitere Informationen finden Sie hier...